文献速递肝病消化道肿瘤与早癌

口服抗病毒药治疗后HCV相关代偿期晚期慢性肝病患者肝脏相关事件的无创预测

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
PubMed 文献 · J Hepatol · 2019-10-17

这项两中心前瞻性研究纳入572例接受直接抗病毒药物(DAA)治疗并获得持续病毒学应答(SVR)的HCV相关代偿期晚期慢性肝病(cACLD)患者,中位随访2.8年,32例(5.6%)发生肝脏相关事件。肝细胞癌(HCC)是最常见事件,随访时白蛋白水平和肝脏硬度值(LSM)可独立预测HCC风险,联合两者可区分不同风险组。

要点

  • DAA治疗后获SVR的cACLD患者仍应监测HCC,其为最常见肝脏相关事件。
  • 随访时LSM≥20 kPa或LSM 10-20 kPa且白蛋白<4.4 g/dl者HCC风险最高。
  • 基线LSM>20 kPa者发生门脉高压相关失代偿,且多数LSM未改善。

核心结论

  • 在DAA治疗获SVR的HCV相关cACLD患者中,HCC是最常见的肝脏相关事件,随访时白蛋白水平和LSM可用于HCC风险分层。

研究设计与样本

  • 两中心前瞻性研究,纳入572例接受DAA治疗并获SVR的cACLD患者,基线LSM≥10 kPa且从未失代偿(Child-Pugh A级),基线和随访1年时进行实验室检查和LSM。

主要发现

  • 中位随访2.8年,32例(5.6%)发生肝脏相关事件。
  • 门脉高压相关失代偿发生率为0.34/100患者年,这些患者基线LSM均>20 kPa,其中4/5随访期间LSM未改善。
  • HCC发生于25例患者,发生率1.5/100患者年。
  • 随访时白蛋白水平(HR 0.08;95%CI 0.02-0.25)和LSM<10 kPa(HR 0.33;95%CI 0.11-0.96)与HCC风险独立相关。
  • 随访时LSM≥20 kPa或LSM 10-20 kPa且白蛋白<4.4 g/dl者HCC风险最高(发生率≥1.9/100患者年)。

关键数值与推荐

  • 随访时LSM≥20 kPa或LSM 10-20 kPa且白蛋白<4.4 g/dl定义为HCC最高风险组(发生率≥1.9/100患者年)。
  • 基线LSM≥10 kPa且Child-Pugh A级为纳入标准。

临床怎么用

  • 对DAA治疗后获SVR的HCV相关cACLD患者,应利用随访时LSM和白蛋白水平进行HCC风险分层。
  • 高风险患者(随访LSM≥20 kPa或LSM 10-20 kPa且白蛋白<4.4 g/dl)应加强HCC监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is important to know which patients with hepatitis C are likely to develop liver-related complications after achieving a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy. We aimed to describe the incidence of liver-related events in a population of patients with HCV-associated compensated advanced chronic liver disease (cACLD) who achieved SVR and to identify non-invasive parameters that predict the occurrence of liver-related events. METHODS: This 2-center prospective study included 572 patients with cACLD who had been treated with DAAs and had achieved SVR. Patients had liver stiffness measurement (LSM) ≥10 kPa at baseline and had never decompensated (Child-Pugh class A). Laboratory work-up and LSM were performed at baseline and at 1 year of follow-up. RESULTS: The median follow-up was 2.8 years during which 32 patients (5.6%) presented with a liver-related event. The incidence rate (IR) of portal hypertension-related decompensation was 0.34/100 patient-years. These patients all had baseline LSM >20 kPa, and LSM did not improve during follow-up in 4 out of 5 of them. Hepatocellular carcinoma (HCC) occurred in 25 patients (IR 1.5/100 patient-years). Albumin levels at follow-up (hazard ratio [HR] 0.08; 95% CI 0.02-0.25) and LSM <10 kPa at follow-up (HR 0.33; 95% CI 0.11-0.96) were independently associated with the risk of HCC. Combining both predictors identified 2 groups with differing risk of HCC occurrence: those with LSM ≥20 kPa at follow-up or those with LSM between 10-20 kPa and albumin levels <4.4 g/dl were at the highest risk (IR ≥1.9/100 patient-years). Visual nomograms predicting HCC risk based on LSM and albumin at 1 year of follow-up were constructed. CONCLUSION: In patients with HCV-related cACLD who have achieved SVR with DAAs, HCC is the most frequent liver-related event. Both albumin levels and LSM are useful for stratifying patients based on their risk of developing HCC during follow-up. LAY SUMMARY: New oral antivirals can cure chronic hepatitis C infection, however patients with advanced chronic liver disease are still at risk of presenting with liver-related complications. The most frequent complication after oral antiviral therapy in asymptomatic patients with advanced chronic liver disease was liver cancer. The use of simple parameters such liver stiffness and albumin levels after treatment can help to identify patients at higher or lower risk of liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Pons M, Rodríguez-Tajes S, Esteban JI, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2019. PMID: 31629779. doi:10.1016/j.jhep.2019.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。